Drug intelligence / Profile preview

BCD-256

Development stage: Phase 1
Lead developer: Biocad
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BCD-256 is a monoclonal antibody targeting BDCA2 (C-Type lectin domain family 4 member C). It acts as a BDCA2 modulator and is being developed for the treatment of systemic lupus erythematosus (SLE), particularly in subjects with skin lesions due to mild to moderate SLE. The drug is currently in Phase 1 clinical trials. Initial development and trials are by Biocad CJSC. Its mechanism involves modulation of BDCA2, which is primarily expressed on plasmacytoid dendritic cells and plays a role in regulating their activity and the type I interferon response in autoimmune diseases[1][2][3][4].

Other names: Anti-BDCA2 BiocadAnti-BDCA-2 BiocadAnti-BDCA 2 Biocad

Targets

CLEC4C (C-type lectin domain family 4 member C)

Beyond the preview

Go deeper on BCD-256.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCD-256.

Explore the full profile